ABL group is pleased to announce the launch of an early access program (EAP) of its first genotyping DeepChek® assay for HCV NS5B. Further reagents will come soon to complete ABL Group’s offer for Sanger and Next Generation Sequencing. These reagents will be completed with data analysis software, ViroScore® and DeepChek®. To know more, please click here.
ABL Group launches early access program
Jul 15, 2015